F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
35 hedge funds and large institutions have $57.7M invested in F-star Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
18% more capital invested
Capital invested by funds: $48.7M → $57.7M (+$9M)
6% more funds holding
Funds holding: 33 → 35 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.91M |
| 2 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$1.23M |
| 3 |
MAM
Morse Asset Management
Darien,
Connecticut
|
+$863K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$534K |
| 5 |
William Blair & Company
Chicago,
Illinois
|
+$528K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TA
Tiedemann Advisors
New York
|
-$4.9M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.35M |
| 3 |
Millennium Management
New York
|
-$677K |
| 4 |
CM
Crestline Management
Fort Worth,
Texas
|
-$510K |
| 5 |
HCM
Highbridge Capital Management
New York
|
-$501K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Northern Trust
Chicago,
Illinois
| $205K | +$174K | +3,046 | New |
|
|
DCM
27
DAFNA Capital Management
Los Angeles,
California
| $110K | +$70.3K | +1,227 | +307% |
|
|
SQA
28
Simon Quick Advisors
Morristown,
New Jersey
| $109K | – | – | – |
|
29
UBS Group
Zurich,
Switzerland
| $34K | -$7.33K | -128 | -20% |
|
|
TDC
30
Thompson Davis & Co
Richmond,
Virginia
| $22K | +$18.6K | +325 | New |
|
|
EWM
31
Evercore Wealth Management
New York
| $17K | – | – | – |
|
32
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $10K | +$8.3K | +145 | New |
|
|
LTFS
33
Ladenburg Thalmann Financial Services
Miami,
Florida
| $8K | – | – | – |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
|
TRCT
35
Tower Research Capital (TRC)
New York
| $3K | +$2.86K | +50 | New |
|
|
TA
36
Tiedemann Advisors
New York
| – | -$4.9M | -90,512 | Closed |
|
|
MIM
37
Monashee Investment Management
Boston,
Massachusetts
| – | -$1.35M | -25,000 | Closed |
|
|
38
Millennium Management
New York
| – | -$677K | -12,499 | Closed |
|
|
VV
39
Verity & Verity
Beaufort,
South Carolina
| – | -$241K | -4,446 | Closed |
|
FSTX Hedge Fund Activity: Q3 2017 in Review
35 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q3 2017, worth a combined $57.7M — up 18% from $48.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new FSTX positions and 4 closed out — a net gain of 2 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.91M. The largest seller was Tiedemann Advisors, exiting entirely with an estimated $4.9M sold.
- 35 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q3 2017, up from 33 in Q2 2017.
- Funds reported $57.7M of F-star Therapeutics, Inc. Common Stock stock for Q3 2017, up 18% quarter-over-quarter.
- 6 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q3 2017 and 4 closed out, a net change of +2 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q3 2017 was Vanguard Group, an estimated $1.91M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q3 2017 was Tiedemann Advisors, an estimated $4.9M sold.
Based on aggregated 13F filings for Q3 2017.